A Guide To Mycosis Fungoides: Signs and Treatments

Mycosis Fungoides is a rare type of skin lymphoma that can mimic everyday rashes.

It often looks like eczema or psoriasis at first, which is why many people go years without a clear diagnosis. This guide explains how to recognize the signs, what it typically looks like, who it affects, how it’s diagnosed, and the treatments your care team might recommend.

What is Mycosis Fungoides?

Mycosis Fungoides (MF) is the most common form of cutaneous T‑cell lymphoma (CTCL), a cancer of immune cells that primarily affects the skin. Despite the name, it is not a fungal infection; the term is a historical misnomer. MF usually grows slowly over many years and often remains limited to the skin for a long time.

In MF, malignant T cells collect in the skin and cause persistent patches or plaques. Some people may eventually develop thicker tumors or, less commonly, involvement of lymph nodes or blood. A very small proportion progress to Sézary syndrome, a related condition with widespread redness and circulating malignant cells.

MF is rare. Estimates vary by region, but incidence is roughly 3–4 cases per million people per year. While it can occur at any age, it’s most commonly diagnosed in adults in their 50s to 60s. It affects men more often than women, and some studies show higher rates among people with darker skin tones.

What does Mycosis Fungoides look like?

The appearance can change over time and varies between individuals. Early on, MF often shows up as flat, scaly patches that can be pink, red, or brown. These patches commonly appear in areas that are usually covered by clothing (buttocks, hips, lower trunk, or thighs) rather than sun-exposed skin. As the disease progresses, patches may become thicker, forming raised plaques, and in some cases nodules or tumors can develop.

Color and texture can differ by skin tone. In darker skin, lesions may look lighter than surrounding skin (hypopigmented), making the patches more subtle. Some variants, like folliculotropic MF, can affect hair follicles and lead to hair loss in affected areas (such as eyebrows) and may cause deeper, acne-like bumps.

Common appearances by stage

Patches: Flat, scaly, often oval patches that may wax and wane. They can resemble eczema but tend to persist.
Plaques: Thicker, raised, scaly areas with more defined borders; may itch or feel sensitive.
Tumors: Dome-shaped, sometimes ulcerated nodules appearing on top of plaques; less common and usually associated with more advanced disease.
Erythroderma: Generalized redness and scaling of most of the skin; uncommon in MF but can occur in advanced cases.

Early signs and symptoms to watch for

Because MF can masquerade as common rashes, the clues are often subtle. Pay attention to:

Persistent patches that don’t fully respond to typical eczema or psoriasis treatments.
Lesions that favor “bathing suit” areas (buttocks, hips, lower trunk, inner thighs) rather than sun-exposed areas.
Asymmetry: patches or plaques more prominent on one side of the body.
Itching (pruritus), which can range from mild to severe, though some people have little or no itch.
Slow evolution over months to years; lesions may come and go but tend to recur in the same places.
Changes in thickness: flat patches becoming raised plaques over time.
New nodules or tender, rapidly growing bumps—these warrant prompt medical evaluation.

Who is most affected?

MF is most commonly diagnosed in adults aged 50–69, with a median age in the late 50s to early 60s. It is rare in children, though pediatric cases do occur. Overall, males are affected more frequently than females. Several studies have reported higher incidence and, in some series, more advanced presentation among Black individuals compared with white individuals, though outcomes vary.

There is no single known cause. Research suggests a combination of genetic susceptibility and environmental factors may play a role, but for most people, no specific trigger is identified.

How is Mycosis Fungoides diagnosed?

Diagnosis relies on a combination of clinical examination, skin biopsies, and specialized tests. Because early MF mimics benign rashes, multiple biopsies over time are sometimes needed to confirm the diagnosis.

What your dermatologist may do

Perform targeted skin biopsies from representative patches or plaques.
Order pathology tests looking for specific patterns of T‑cell infiltration and immunophenotyping (for example, CD3+, CD4+ cells with loss of certain markers like CD7).
Request T‑cell receptor (TCR) gene rearrangement studies to detect a clonal T‑cell population.
Stage the disease using TNMB (Tumor, Node, Metastasis, Blood) criteria if MF is confirmed.
Check blood tests and, if indicated, imaging to evaluate lymph nodes or internal organ involvement.

If the diagnosis is uncertain, your clinician may treat empirically for dermatitis and re-biopsy later. Keeping a timeline and photos of your lesions can help your doctor choose the best sites to sample.

Treatment options

Treatment is personalized based on stage, symptoms, and your overall health. Many people with early-stage MF (patch/plaque disease) can be managed effectively with skin-directed therapies. Advanced disease may require systemic treatments. Your care team may combine approaches to improve control and comfort.

Skin-directed therapies (often first-line for early MF)

Topical corticosteroids to reduce inflammation and itch.
Topical chemotherapy, such as mechlorethamine (nitrogen mustard) gel.
Topical retinoids (e.g., bexarotene gel) in selected cases.
Phototherapy: narrowband UVB for patch-stage disease or PUVA for thicker plaques; given several times per week in a clinic.
Localized radiation for resistant plaques or small tumors; total skin electron beam therapy (TSEB) may be used in more extensive skin disease.

Systemic and advanced options

Oral retinoids (bexarotene) or low-dose methotrexate.
Biologic and targeted therapies (varies by region and indication), such as interferon‑alpha, histone deacetylase inhibitors (vorinostat, romidepsin), monoclonal antibodies (mogamulizumab; brentuximab vedotin for CD30‑positive disease), and others.
Extracorporeal photopheresis, particularly in patients with blood involvement or erythroderma.
Clinical trials exploring novel agents and combinations.
Allogeneic stem cell transplantation in selected, advanced, or refractory cases after specialist evaluation.

Relief of symptoms and skin care

Regular moisturizers and gentle cleansers to reduce dryness and scaling.
Antihistamines or prescription agents to control itching.
Watch for signs of skin infection (increasing pain, warmth, pus) and seek care promptly.
Sun protection and avoidance of skin trauma to reduce irritation.

Most people experience periods of remission and flare. Even when the condition is chronic, many can maintain good quality of life with the right regimen and follow-up.

Prognosis

Outcomes vary by stage. In early-stage MF confined to the skin, long-term survival is common, and many patients live a normal lifespan. More advanced stages require closer monitoring and may carry a higher risk of complications. Your dermatologist and oncologist can discuss your individual outlook and the best plan to keep your skin comfortable and the disease controlled.

When to see a doctor

A persistent, scaly rash in “bathing suit” areas that doesn’t fully respond to standard creams.
Patches or plaques that are slowly thickening or new nodules developing.
Severe or worsening itch, redness covering large body areas, or signs of infection.
A previous biopsy was inconclusive but your rash persists—ask about repeat or deeper biopsies.

Bring a list of prior treatments, photos documenting changes, and note which areas are most symptomatic. Early specialist input can shorten the path to diagnosis.

Key takeaways

Mycosis Fungoides is a rare skin lymphoma that often mimics eczema or psoriasis.
Look for persistent, asymmetric patches or plaques on covered skin areas, especially if standard treatments fail.
Diagnosis may require multiple biopsies and specialized testing.
Early-stage disease is usually managed with skin-directed therapies; advanced cases may need systemic treatments.
Regular follow-up and symptom control help maintain quality of life.